PATENT CLAIM ANALYSIS

Application Number: 16146762
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["424", "451000"]

Abstract:
The present invention relates generally to the field of using udenafil or a pharmaceutically acceptable salt thereof in patients who have undergone the Fontan operation.

Claim (Index 67):
Use of an effective dose of udenafil, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a human patient, who has undergone Fontan palliation for improving the human patient's exercise capacity, wherein the human patient's exercise capacity is adversely affected due to a decline in the human patient's myocardial function after the Fontan palliation, wherein the human patient is in need of treatment to improve the human patient's exercise capacity, and wherein the medicament is formulated for administration with an effective dose of udenafil, or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 287.0
- Percentile: 97.0
- Lexical Diversity: 1.04
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15887523', '14788211', '14079548', '15671653', '14442711']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7391622867952051
- 35 USC 102 Novelty (BERT): 0.6612503892654941
- Combined Prediction Score: 0.731371097042234
- Mean Citation Score: 425.65413
- Max Citation Score: 788.03906
- Similarity Product: 597.3328687234425

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test